본문 바로가기
KERD
논문KCI 등재

Monkeypox: the resurgence of forgotten things

백경란|Jung Jaehun|Kim Sun Bean
한국역학회 (Korean Society of Epidemiology)|2022.01|Epidemiology and Health|제44권 |pp. 1-14|DOI 10.4178/epih.e2022082

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

VaccinationTherapeuticsClinical featuresMonkeypox virus

초록

Monkeypox, a rare zoonotic disease, is prevalent primarily in Central and Western Africa. However, as the 2022 monkeypox outbreak is the first incidence of widespread community transmission outside Africa, monkeypox is emerging as a worldwide concern. Monkeypox is caused by the monkeypox virus, which belongs to the genus orthopoxvirus and presents as a vesicular-pustular disease that may be preceded by fever, malaise, and other constitutional symptoms. If present, lymphadenopathy may distinguish it from chickenpox or smallpox. However, contrary to previous manifestations, most monkeypox patients presented with atypical features during the 2022 outbreak. Monkeypox is usually a self-limiting disease with symptoms lasting between 2 and 4 weeks and is mainly transmitted when a person is in contact with an infected animal, person, or fomites contaminated with the virus. Very few treatment options are available for treating this disease. Tecovirimat has been licensed in some countries for the treatment of smallpox and monkeypox infections. Two other medications, cidofovir and brincidofovir, were effective against poxviruses in in vitro and animal studies, but data on human cases of monkeypox are limited. Although Imvamune (JYNNEOS), a vaccine against monkeypox, is authorized in the United States, there are currently no established routine vaccination programs. Current preventive strategies focus on the detection of probable cases and containment of the outbreak through the implementation of selected ring vaccination programs. Fundamental principles to prevent the spread of monkeypox, including maintaining personal hygiene and avoiding close contact with symptomatic patients, are of paramount importance.

Abstract

Monkeypox, a rare zoonotic disease, is prevalent primarily in Central and Western Africa. However, as the 2022 monkeypox outbreak is the first incidence of widespread community transmission outside Africa, monkeypox is emerging as a worldwide concern. Monkeypox is caused by the monkeypox virus, which belongs to the genus orthopoxvirus and presents as a vesicular-pustular disease that may be preceded by fever, malaise, and other constitutional symptoms. If present, lymphadenopathy may distinguish it from chickenpox or smallpox. However, contrary to previous manifestations, most monkeypox patients presented with atypical features during the 2022 outbreak. Monkeypox is usually a self-limiting disease with symptoms lasting between 2 and 4 weeks and is mainly transmitted when a person is in contact with an infected animal, person, or fomites contaminated with the virus. Very few treatment options are available for treating this disease. Tecovirimat has been licensed in some countries for the treatment of smallpox and monkeypox infections. Two other medications, cidofovir and brincidofovir, were effective against poxviruses in in vitro and animal studies, but data on human cases of monkeypox are limited. Although Imvamune (JYNNEOS), a vaccine against monkeypox, is authorized in the United States, there are currently no established routine vaccination programs. Current preventive strategies focus on the detection of probable cases and containment of the outbreak through the implementation of selected ring vaccination programs. Fundamental principles to prevent the spread of monkeypox, including maintaining personal hygiene and avoiding close contact with symptomatic patients, are of paramount importance.

참고문헌 (100)

  1. "Monkeypox" (2022)[URL]
  2. Mahase E, "What do we know about the outbreaks in Europe and North America?", BMJ, 377, pp.o1274~ (2022)[DOI]
  3. Ihekweazu C, "Importance of epidemiological research of monkeypox : is incidence increasing", Expert Rev Anti Infect Ther, 18(5), pp.389~392 (2020)[DOI]
  4. "Multi-country outbreak of monkeypox, External situation report #3 - 10 August 2022"[URL]
  5. "WHO Director-General’s statement at the press conference following IHR Emergency Committee regarding the multicountry outbreak of monkeypox - 23 July 2022"[URL]
  6. Jezek Z, "Human monkeypox" (1988), Karger Publishers
  7. Ježek Z, "Human monkeypox : clinical features of 282 patients", J Infect Dis, 156(2), pp.293~298 (1987)[DOI]
  8. Reynolds MG, "Outbreaks of human monkeypox after cessation of smallpox vaccination", Trends Microbiol, 20(2), pp.80~87 (2012)
  9. Petersen E, "Human monkeypox : epidemiologic and clinical characteristics, diagnosis, and prevention", Infect Dis Clin North Am, 33(4), pp.1027~1043 (2019)[DOI]
  10. "Monkeypox multi-country outbreak" (2022)[URL]
  11. Karem KL, "Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection", Clin Vaccine Immunol, 14(10), pp.1318~1327 (2007)[DOI]
  12. "irus Taxonomy: 2021 Release" (2021)[URL]
  13. Likos AM, "A tale of two clades : monkeypox viruses", J Gen Virol, 86(pt10), pp.2661~2672 (2005)[DOI]
  14. Sklenovska N, "Emergence of monkeypox as the most important orthopoxvirus infection in humans", Front public health, 6, pp.241~ (2018)[DOI]
  15. Huhn GD, "Clinical characteristics of human monkeypox, and risk factors for severe disease", Clin Infect Dis, 41(12), pp.1742~1751 (2005)[DOI]
  16. Yinka-Ogunleye A, "Outbreak of human monkeypox in Nigeria in 2017–18 : a clinical and epidemiological report", Lancet Infect Dis, 19(8), pp.872~879 (2019)[DOI]
  17. Erez N, "Diagnosis of imported monkeypox, Israel, 2018", Emerg Infect Dis, 25(25), pp.980~983 (2019)[DOI]
  18. Yong SEF, "Imported Monkeypox, Singapore", Emerg Infect Dis, 26(8), pp.1826~1830 (2020)
  19. Damon IK., "Status of human monkeypox: clinical disease, epidemiology and research", Vaccine, 29(Suppl 4), pp.D54~D59 (2011)[DOI]
  20. Saijo M, "Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates", J Gen Virol, 90(pt9), pp.2266~2271 (2009)[DOI]
  21. Kozlov M, "Monkeypox goes global : why scientists are on alert", Nature, 606(7912), pp.15~16 (2022)[DOI]
  22. Simpson K, "Human monkeypox–After 40 years, an unintended consequence of smallpox eradication", Vaccine, 38(33), pp.5077~5081 (2020)[DOI]
  23. "First draft genome sequence of Monkeypox virus associated with the suspected multi-country outbreak, May 2022 (confirmed case in Portugal)" (2022)[URL]
  24. Mauldin MR, "Exportation of monkeypox virus from the African continent", J Infect Dis, 225(8), pp.1367~1376 (2022)[DOI]
  25. Isidro J, "Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus", Nat Med (2022)[DOI]
  26. "Multiple lineages of Monkeypox virus detected in the United States, 2021-2022" (2022)[URL]
  27. Minhaj FS, "Monkeypox outbreak—nine states, May 2022", MMWR Morb Mortal Wkly Rep, 71(23), pp.764~769 (2022)[DOI]
  28. "Multi-country monkeypox outbreak: situation update" (2022)[URL]
  29. "Monkeypox in Animals" (2022)[URL]
  30. Frey SE, "Poxvirus zoonoses--putting pocks into context", N Engl J Med, 350(4), pp.324~327 (2004)[DOI]
  31. "Multi-country monkeypox outbreak in non-endemic countries: Update" (2022)[URL]
  32. Alakunle E, "Monkeypox virus in Nigeria : infection biology, epidemiology, and evolution", Viruses, 12(11), pp.1257~ (2020)[DOI]
  33. Kantele A, "Emerging diseases—the monkeypox epidemic in the Democratic Republic of the Congo", Clin Microbiol Infect, 22(8), pp.658~659 (2016)[DOI]
  34. Mbala PK, "Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo", J Infect Dis, 216(7), pp.824~828 (2017)[DOI]
  35. "Multi-country monkeypox outbreak in non-endemic countries" (2022)[URL]
  36. Antinori A, "Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022", Euro Surveill, 27(22), pp.2200421~ (2022)[DOI]
  37. "How its spreads" (2022)[URL]
  38. McCollum AM, "Human monkeypox", Clin Infect Dis, 58(2), pp.260~267 (2014)[DOI]
  39. Otu A, "Global human monkeypox outbreak : atypical presentation demanding urgent public health action", The Lancet Microbe (2022)[DOI]
  40. Girometti N, "Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis", Lancet Infect Dis (2022)[DOI]
  41. "Monkeypox" (2022)[URL]
  42. Petersen B, "Smallpox, monkeypox, and other poxvirus infections. Goldman-Cecil Medicine" (2020), Elsevier
  43. "Monkeypox" (2019)[URL]
  44. Ryan ET, "Hunter’s tropical medicine and emerging infectious diseases" (2019), Elsevier
  45. "Weekly Bulletin on Outbreaks and Other Emergencies" (2022)[URL]
  46. Basgoz N, "Case 24-2022 : A 31-Year-Old Man with Perianal and Penile Ulcers, Rectal Pain, and Rash", N Engl J Med (2022)[DOI]
  47. Gordon SN, "Smallpox vaccine safety is dependent on T cells and not B cells", J Infect Dis, 203(8), pp.1043~1053 (2011)[DOI]
  48. Koplan JP, "Smallpox : clinical types, causes of death, and treatment", J Infect Dis, 140(3), pp.440~441 (1979)[DOI]
  49. "WHO Global Consultation - Monkeypox Vaccine Study Designs objective"[URL]
  50. Ježek Z, "Clinico-epidemiological features of monkeypox patients with an animal or human source of infection", Bull World Health Organ, 66(4), pp.459~464 (1988)
  51. Beer EM, "A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy", PLoS Negl Trop Dis, 13(10), pp.e0007791~ (2019)[DOI]
  52. Di Giulio DB, "Human monkeypox : an emerging zoonosis", Lancet Infect Dis, 4(4), pp.15~25 (2004)[DOI]
  53. Li Y, "Detection of monkeypox virus with real-time PCR assays", J Clin Virol, 36(3), pp.194~203 (2006)
  54. Shchelkunov SN, "Species-specific identification of variola, monkeypox, cowpox, and vaccinia viruses by multiplex real-time PCR assay", J Virol Methods, 175(2), pp.163~169 (2011)[DOI]
  55. Karem KL, "Characterization of acute-phase humoral immunity to monkeypox : use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak", Clin Diagn Lab Immunol, 12(7), pp.867~872 (2005)
  56. "Laboratory Procedures and Biosafety Guidelines" (2022)[URL]
  57. "Laboratory testing for the monkeypox virus: Interim guidance" (2022)[URL]
  58. "Interim clinical guidance for the treatment of monkeypox" (2022)[URL]
  59. Stittelaar KJ, "Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection", Nature, 439(7077), pp.745~747 (2006)[DOI]
  60. Petersen BW, "Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses—recommendations of the Advisory Committee on Immunization Practices(ACIP), 2015", MMWR Morb Mortal Wkly Rep, 65(10), pp.257~262 (2016)
  61. Cono J, "Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies", Emerg Infect Dis, 12(11), pp.1631~1637 (2006)[DOI]
  62. Ogoina D, "Clinical course and outcome of human monkeypox in Nigeria", Clin Infect Dis, 71(8), pp.e210~e214 (2020)[DOI]
  63. Kozlov M, "Monkeypox vaccination begins-can the global outbreaks be contained", Nature, 606(7914), pp.444~445 (2022)[DOI]
  64. Adler H, "Clinical features and management of human monkeypox : a retrospective observational study in the UK", Lancet Infect Dis (2022)[DOI]
  65. Yang G, "An orally bioavailable antipoxvirus compound(ST-246)inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge", J Virol, 79(20), pp.13139~13149 (2005)[DOI]
  66. Duraffour S, "Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures", Antivir Ther, 12(8), pp.1205~1216 (2007)
  67. Mucker EM, "Efficacy of tecovirimat(ST-246)in nonhuman primates infected with variola virus(Smallpox)", Antimicrob Agents Chemother, 57(12), pp.6246~6253 (2013)[DOI]
  68. Quenelle DC, "Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice", Antimicrob Agents Chemother, 51(2), pp.689~695 (2007)[DOI]
  69. Sbrana E, "Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection", Am J Trop Med Hyg, 76(4), pp.768~773 (2007)
  70. Huggins J, "Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246", Antimicrob Agents Chemother, 53(6), pp.2620~2625 (2009)[DOI]
  71. Grosenbach DW, "Oral tecovirimat for the treatment of smallpox", N Engl J Med, 379(1), pp.44~53 (2018)
  72. Nalca A, "Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model", Antiviral Res, 79(2), pp.121~127 (2008)[DOI]
  73. Russo AT, "Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques", J Infect Dis, 218(9), pp.1490~1499 (2018)[DOI]
  74. "FDA Approves the First Drug with an Indication for Treatment of Smallpox. FDA News Release 2018" (2018)[URL]
  75. Vora S, "Severe eczema vaccinatum in a household contact of a smallpox vaccinee", Clin Infect Dis, 46(10), pp.1555~1561 (2008)[DOI]
  76. Lindholm DA, "Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukemia After Smallpox Vaccination", Clin Infect Dis, 69(12), pp.2205~2207 (2019)[DOI]
  77. Kiernan M, "Orbital cowpox", N Engl J Med, 384(23), pp.2241~ (2021)[DOI]
  78. "SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials" (2022)[URL]
  79. "FDA approves drug to treat smallpox" (2022)[URL]
  80. Hutson CL, "Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model", mSphere, 6(1), pp.e00927~e01020 (2021)[DOI]
  81. FDA, "FDA approves cidofovir for treatment of CMV retinitis", J Int Assoc Phys AIDS Care, 2(8), pp.30~ (1996)
  82. Baker RO, "Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections", Antiviral Res, 57(1-2), pp.13~23 (2003)[DOI]
  83. Smee DF, "Progress in the discovery of compounds inhibiting orthopoxviruses in animal models", Antiviral Chemistry and Chemotherapy, 19(3), pp.115~124 (2008)[DOI]
  84. Rao AK., "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022", MMWR Morb Mortal Wkly Rep, 71(22), pp.734~742 (2022)[DOI]
  85. Fleischauer AT, "Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers", Clin Infect Dis, 40(5), pp.689~694 (2005)[DOI]
  86. Kretzschmar M, "Ring vaccination and smallpox control", Emerging infectious diseases, 10, pp.832~ (2004)
  87. "Second Ebola vaccine to complement “ring vaccination”given green light in DRC" (2019)[URL]
  88. "Vaccines and immunization for monkeypox: interim guidance, 14 June 2022" (2022)[URL]
  89. Kwon Seunghyun Lewis, "Monkeypox Vaccination in the Republic of Korea: Identifying the High-Risk Target Group", Journal of Korean Medical Science, 37(29), pp.1~4 (2022), 대한의학회[DOI]
  90. Heymann DL, "Re-emergence of monkeypox in Africa : a review of the past six years", Br Med Bull, 54(3), pp.693~702 (1998)[DOI]
  91. Hammarlund E, "Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox", Nat Med, 11(9), pp.1005~1011 (2005)[DOI]
  92. Oh MD, "Milestones in history of adult vaccination in Korea", Clin Exp Vaccine Res, 1(1), pp.9~17 (2012)[DOI]
  93. "Vaccinia Immune Globulin Intravenous (Human). FDA News Release 2018" (2018)[URL]
  94. "Orthopoxvirus vaccine guidance for persons at risk for occupational Exposure" (2022)[URL]
  95. CDC, "Multistate outbreak of monkeypox--Illinois, Indiana, and Wisconsin, 2003", MMWR Morb Mortal Wkly Rep, 52(23), pp.537~540 (2003)
  96. Rimoin AW, "Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo", Proc Natl Acad Sci U S A, 107(37), pp.16262~16267 (2010)[DOI]
  97. "Monkeypox and Smallpox Vaccine Guidance" (2022)[URL]
  98. Jamieson DJ, "The Role of the Obstetrician–Gynecologist in Emerging Infectious Diseases : Monkeypox and Pregnancy", Obstet Gynecol, 103(4), pp.754~756 (2004)[DOI]
  99. "Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022" (2022)[URL]
  100. Young Rock Jang, "The First Case of Monkeypox in the Republic of Korea", Journal of Korean Medical Science, 37(27), pp.1~4 (2022), 대한의학회[DOI]

관련 논문AI추천

Monkeypox and Its Recent OUTBREAKS; A Systemic ReviewAbedien Zain Ul, Gul Kainat, Rahman Khizar, Shafiq Maheen한국미생물·생명공학회 · 한국미생물·생명공학회지2022 · 제50권 제4호Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for the Re-Emerging Human Monkeypox Virus안대균, Kim Seong-Jun, Kim Yu-Jin, Lee Su Jin, Lee Wooseong한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2023 · 제33권 제8호A Case of Human Mpox with Isolated Perianal Ulcers Development in Convalescent PhaseChin Bum Sik, Choi Jae-Phil, Jeon Jaehyun, Kim Hyang Su, Kim Jin Seok, Kim Min-Kyung, Kim Yeonjae, Park Jun-Sun, Um Jihye, Yim Hong Soon대한감염학회 · Infection and Chemotherapy2023 · 제55권 제1호Is Human Mpox a New Sexually Transmitted Infection in Korea That Should Be Monitored?Gilho Lee대한요로생식기감염학회 · Urogenital Tract Infection2023 · 제18권 제2호Guidelines for the Laboratory Diagnosis of Monkeypox in Korea김택수, 류남희, 성문우, 성흥섭, 유천권, 이혁민, 허희재, Committee of Management of Laboratory Tests for Infectious Diseases, Hong Ki Ho, Kim Gab Jung, Kim Hyun Soo, Kim Jae-Seok, Kim So Yeon, Korea Disease Control and Prevention Agency, Korean Society for Laboratory Medicine, and the Bureau of Infectious Disease Diagnosis Control, Lee Jaehyeon, Park Jae-Sun, Park Ok Kyu, Park Younhee, Roh Kyoung Ho대한진단검사의학회 · Annals of Laboratory Medicine2023 · 제43권 제2호Poxvirus under the eyes of electron microscope현재경한국현미경학회 · Applied Microscopy2022 · 제52권 제1호

이 간행물의 다른 논문 (112건)

Socioeconomic inequality in compliance with precautions and health behavior changes during the COVID-19 outbreak: an analysis of the Korean Community Health Survey 2020양재원, Kim Hyeon Chang, Jung Sun Jae, 이가빈, YANG YIYI, Hoang Thang Manhpp. 1-8Model-based cost-effectiveness analysis of oral antivirals against SARS-CoV-2 in KoreaHuh Kyungmin, Kim Sun Bean, 유진홍, 백경란, 정재훈, Jo Youngji, Radnaabaatar Munkhzul, Park Hojunpp. 1-10Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional surveyChoe Seung-Ah, 이상원, 신주영, 김주환, 윤동원, 최영준, Noh Yunha, Jung Jaehunpp. 1-8Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: a special report of the 2020 Korea National Health and Nutrition Examination SurveyKim Yoonjung, Kim Hyeon Chang, Park Suyeon, Oh Kyungwon, 이가빈pp. 1-8The Korea National Health and Nutrition Examination Survey data linked Cause of Death dataOh Kyungwon, Yun Sunghapp. 1-7
원문 보기